NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis $2.37 -0.02 (-0.63%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BDRX alerts:Sign Up Key Stats Today's Range$2.36▼$2.4250-Day Range$2.38▼$10.6452-Week Range$2.28▼$357.60Volume7,141 shsAverage Volume215,511 shsMarket Capitalization$307.45 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a specialty pharmaceutical company focused on developing and commercializing therapies for rare and difficult-to-treat diseases, with an emphasis on oncology and neurological conditions. The company’s programs are designed to address areas where existing treatment options are limited. Biodexa has developed drug-delivery technologies intended to improve the administration, targeting and duration of pharmaceutical treatments. Its portfolio has included Q-Sphera, a platform for producing long-acting injectable medicines, as well as development programs involving therapies delivered directly to tumors or the central nervous system. Historically known as Midatech Pharma plc, the company changed its name to Biodexa Pharmaceuticals plc as it pursued a broader development strategy. Its pipeline has included investigational oncology programs such as MTX110, an intratumoral formulation of panobinostat studied for diffuse intrinsic pontine glioma, a rare pediatric brain cancer. Biodexa is headquartered in the United Kingdom and has conducted development activities through international clinical and research collaborations.AI Generated. May Contain Errors. Read More Biodexa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreBDRX MarketRank™: 1.046983379135 of 5 starsBiodexa Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBiodexa Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBiodexa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Biodexa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioBiodexa Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.46% of the float of Biodexa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently decreased by 99.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodexa Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiodexa Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.93 News SentimentBiodexa Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biodexa Pharmaceuticals this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.Percentage Held by Institutions17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.Read more about Biodexa Pharmaceuticals' insider trading history. Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDRX Stock News HeadlinesBiodexa provides R&D UpdateNovember 9, 2026 | globenewswire.comBiodexa Pharmaceuticals PLC - Depositary receipt price target increased by 700.00% to $73.44November 2, 2026 | msn.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.November 13 at 1:00 AM | Crypto 101 Media (Ad)Biodexa Enrolls 100 Patients In Phase 3 ERapa Trial For FAPOctober 13, 2026 | rttnews.comBiodexa reaches 100-patient enrollment milestone in phase 3 Serenta trial as key analysis timeline acceleratesOctober 13, 2026 | msn.comBiodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAPOctober 13, 2026 | globenewswire.comBDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 PatientsSeptember 22, 2026 | finance.yahoo.comBiodexa Enters Warrant Exercise Deal For $2 Mln As Phase 3 For ERapa Progresses; Stock Plunges 25%September 16, 2026 | rttnews.comSee More Headlines BDRX Stock Analysis - Frequently Asked Questions How have BDRX shares performed this year? Biodexa Pharmaceuticals' stock was trading at $90.80 at the beginning of 2026. Since then, BDRX shares have decreased by 97.4% and is now trading at $2.3650. How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) released its earnings results on Thursday, September, 10th. The company reported ($640,000.00) earnings per share for the quarter. When did Biodexa Pharmaceuticals' stock split? Biodexa Pharmaceuticals's stock reverse split on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, March 18th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), NIO (NIO), Nokia (NOK), Nikola (NKLAQ), Advanced Micro Devices (AMD) and Corbus Pharmaceuticals (CRBP). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BDRX's financial health is in the Red zone, according to TradeSmith. BDRX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BDRX Previous SymbolLON:MTPH CIK1643918 Webwww.biodexapharma.com Phone441235888300FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick RatioN/A Sales & Book Value Annual Sales$470 thousand Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book Value$882.39 per share Price / Book0.00Miscellaneous Outstanding Shares130,000Free Float129,000Market Cap$308.10 thousand OptionableNot Optionable Beta1.25 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BDRX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDRX Stock Alerts